55 terminated. 55 Phase 2, 11 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 55 | Terminated 55 |
| Phase 1 | 11 | Terminated 11 |
Follow Sunitinib: new trials by email Literature Review of Sunitinib trials Research Report on Sunitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sunitinib in Sarcomas of the Central Nervous System Sunitinib, wGT3x-BT - Gliosarcoma, Central Nervous System Sarcoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2019-02-21 | 2022-04-19 |
| Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control Nivolumab, Sunitinib, Pazopanib - Metastatic Renal Cell Carcinoma | Phase 2 | Terminated | AIO-Studien-gGmbH | 49 | 2016-12-01 | 2021-09-08 |
| Personalized Targeted Inhibitors Treatment in Renal Cell Cancer Sunitinib, Temsirolimus, Sorafenib - Carcinoma, Renal Cell | Phase 2 | Terminated | The University of Texas Health Science Center, Houston | 4 | 2016-01-04 | 2018-10-12 |
| A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population Sunitinib malate - Renal Cell Carcinoma | Phase 2 | Terminated | vghtpe user | 13 | 2015-08-12 | 2018-06-26 |
| Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery Sunitinib, Everolimus - Neuroendocrine Tumors, Neuroendocrine Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 16 | 2015-04-08 | 2020-09-09 |
| Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study) Sorafenib or Sunitinib - Renal Cancer Cell | Phase 2 | Terminated | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 18 | 2014-11-01 | 2018-03-07 |
| Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer Sunitinib, Everolimus - Metastatic Renal Cell Carcinoma | Phase 2 | Terminated | Associació per a la Recerca Oncologica, Spain | 41 | 2013-02-12 | 2017-10-02 |
| Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma Sunitinib - Metastatic Renal Cell Carcinoma | Phase 2 | Terminated | Amsterdam UMC, location VUmc | 5 | 2012-10-01 | 2017-04-07 |
| A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC Tivozanib, Sunitinib - Metastatic Renal Cell Carcinoma | Phase 2 | Terminated | AVEO Pharmaceuticals, Inc. | 58 | 2012-07-01 | 2020-10-27 |
| Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Antitumor Drug Screening Assay, Dasatinib, Idelalisib - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia | Phase 2 | Terminated | OHSU Knight Cancer Institute | 12 | 2012-05-11 | 2021-11-04 |
| A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma LY2510924, Sunitinib - Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | Eli Lilly and Company | 110 | 2011-08-01 | 2019-07-23 |
| Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) Sunitinib, Placebo - Renal Cell Carcinoma, Pulmonary Metastases | Phase 2 | Terminated | Association of Urologic Oncology (AUO) | 60 | 2010-10-01 | 2026-08-25 |
| Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma Everolimus, Sunitinib - Kidney Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 73 | 2010-08-01 | 2021-04-28 |
| Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer Exemestane, Sutent - Metastatic Breast Cancer | Phase 1 / Phase 2 | Terminated | Baylor Breast Care Center | 4 | 2010-03-01 | 2020-07-24 |
| Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma Sutent - Hepatocellular Carcinoma, Fibrolamellar Hepatocellular Carcinoma | Phase 2 | Terminated | Assistance Publique - Hôpitaux de Paris | 4 | 2009-10-01 | 2014-03-13 |
| A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma CVX-060 + sunitinib, Sunitinib - Solid Tumor | Phase 2 | Terminated | Pfizer | 34 | 2009-09-01 | 2015-11-20 |
| Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma Lenalidomide, Sunitinib - Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Celgene | 16 | 2009-09-01 | 2019-11-25 |
| Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy Sunitinib - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Terminated | University of Michigan | 7 | 2009-09-01 | 2017-06-28 |
| Sunitinib and Capecitabine for First Line Colon Cancer sunitinib and capecitabine - Metastatic Colorectal Cancer | Phase 2 | Terminated | Georgetown University | 50 | 2009-08-01 | 2025-02-12 |
| Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients sunitinib malate, docetaxel, prednisone - Prostate Cancer, Adenocarcinoma of the Prostate | Phase 1 / Phase 2 | Terminated | John P. Fruehauf | 4 | 2009-07-01 | 2017-02-01 |
Showing 20 of 55. Sign in to see all of them.
Carcinoma, Renal Cell (16) · Breast Neoplasms (6) · Neoplasm Metastasis (6) · Neoplasms (6) · Brain Neoplasms (4) · Carcinoma (3) · Carcinoma, Hepatocellular (3) · Colorectal Neoplasms (3) · Liver Neoplasms (3) · Melanoma (3) · Urinary Bladder Neoplasms (3) · Adenocarcinoma (2) · Digestive System Neoplasms (2) · Kidney Neoplasms (2) · Leukemia, Myeloid, Acute (2)
National Cancer Institute (NCI) (4) · Genentech, Inc. (3) · M.D. Anderson Cancer Center (3) · Pfizer (3) · Assistance Publique - Hôpitaux de Paris (2) · Baylor Breast Care Center (2) · Case Comprehensive Cancer Center (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · University of California, San Francisco (2) · AIO-Studien-gGmbH (1) · AVEO Pharmaceuticals, Inc. (1) · Amsterdam UMC, location VUmc (1) · Associació per a la Recerca Oncologica, Spain (1) · Association of Urologic Oncology (AUO) (1) · Celgene (1)
United States (39) · France (5) · Germany (5) · Belgium (2) · Canada (2) · Italy (2) · Netherlands (2) · Spain (2) · United Kingdom (2) · Austria (1) · Denmark (1) · Greece (1) · Japan (1) · Taiwan (1)
Hope S. Rugo, MD (2) · Adil Daud, M.D. (1) · Aiwu Ruth He, MD (1) · Amado Zurita, MD (1) · Andrew J Armstrong, MD, ScM (1) · Andrew X. Zhu, MD (1) · Antonio Finelli, MD MSc FRCSC (1) · Catherine Meyerle, MD (1) · David M. Peereboom, MD (1) · Debora Barton, MD (1) · Egbert F. Smit, MD (1) · Eric Jonasch, MD (1)
PMID 22105611, PMID 23228446, PMID 24249435, PMID 24914044, PMID 25085632, PMID 25991462, PMID 26109878, PMID 26678657, PMID 27154357, PMID 30865533, PMID 31231785, PMID 32654362, PMID 33058158, PMID 33207247, PMID 37758574
2008 (2), 2014 (1), 2016 (1), N01CM62202 (1), P30CA043703 (1), P30CA072720 (1), R21CA159265 (1)